Universal Precautions in Pain Management: *A Person-Centered Approach to Preventing Opioid Misuse*

May 18, 2023 11am-12pm

This material was prepared by the IPRO QIN-QIO, a Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication #12SOW-IPRO-QIN-TA-A1-23-1029



Today's Speakers



Rebekah Gardner, MD Senior Medical Scientist Healthcentric Advisors



Jennifer McCarthy, EdD, LCPC Grants and Contracts Manager New England Rural Health Association



Marghie Giuliano, R.Ph. Medication Safety Pharmacist Healthcentric Advisors



Chat In


Please use the chat feature to share your name, organization, and state.



We want to know who is around the table



Increase in Drug Overdose Deaths in US




Atric
 Quality Innovation Network Quality Innovation Network Quality Improvement Organizations
 CENTERS FOR MEDICARE & MEDICAID SERVICES
 IQUALITY IMPROVEMENT & INNOVATION GROUP

Qlarant

QIN-QIO

https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Pandemic Erased Moderate Gains





https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Variation Across New England






 Image: Property of the system
 Image: Property of the system

https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Percent Change in Deaths in the Past Year








IPRO Healthcentric Advisors QIN-QO Qlarant Quality Innovation Network - Quality Improvement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IQUALITY IMPROVEMENT & INNOVATION GROUP


https://www.hhs.gov/overdose-prevention/



Synthetic opioid (including fentanyl) overdose deaths increased 97-fold

Psychostimulant (primarily methamphetamine) overdose deaths increased **59-fold**






Synthetic opioid (including fentanyl) overdose deaths increased 97-fold

Psychostimulant (primarily methamphetamine) overdose deaths increased **59-fold**

Cocaine overdose deaths increased 6.4-fold





Synthetic opioid (including fentanyl) overdose deaths increased 97-fold

Psychostimulant (primarily methamphetamine) overdose deaths increased **59-fold**

Cocaine overdose deaths increased 6.4-fold

Rx opioid overdose deaths increased 4.9-fold



Learning Objectives

Upon attending this session, participants will be able to:

1

3

- Implement evidence-based assessments of patients' physical and behavioral needs
- Describe a holistic treatment plan
- Access tools and resources to better support patients and the community



Our Opioid Framework*

Primary Prevention

Harm Reduction

Evidence-Based Treatment

Recovery Support

*Based on the Department of Health & Human Services Overdose Prevention Strategy

Chat In


What are your goals for this session?



We want this time to be of value to you



The Case of Mr. Davani




72 y.o. man with GERD, CAD, CKD, and depression

Here to discuss worsening pain from hip osteoarthritis

Orthopedist is considering hip replacement



Assess physiological and behavioral needs and risks






Quality Innovation Network -Quality Improvement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IOUALITY IMPROVEMENT & INNOVATION GROUP

Assess physiological and behavioral needs and risks

Identify patient-centered **treatment** plan that reduces both suffering and unintended harm






Assess physiological and behavioral needs and risks

Identify patient-centered **treatment** plan that reduces both suffering and unintended harm

Implement and **refer**, as needed, including complementary therapies





Assess physiological and behavioral needs and risks

Identify patient-centered **treatment** plan that reduces both suffering and unintended harm

Implement and **refer**, as needed, including complementary therapies Follow up to provide support and **monitor progress**





Screening & Assessment

Jennifer McCarthy, EdD, LCPC Grants and Contracts Manager New England Rural Health Association



Screening & Assessment

- Start with pain
- Reflect on relationship between pain and mental health
- Review mental health screens
- Explore findings from the Harvard Study on happiness
- Consider social screens
- Examine substance use screens






Use OPQRST as a Conversation Starter

O nset	Did your pain start suddenly or gradually get worse? What were you doing when the pain started?					
Provocation .	What makes your pain better or worse?					
Q uality •	What words would you use to describe your pain? Is it dull or sharp?					
Region .	Point to where it hurts the most. Where does your pain go from there?					
Severity	On a scale of 1 to 10, how would you rate this pain?					
Time .	How long has this been going on?					

IQUALITY IMPROVEMENT & INNOVATION GROUP

QIN-QIO

A Patient-Centered Approach



- Pain is subjective and relative for each individual patient
- · All pain is valid



The Pain, Enjoyment of Life, and General Activity (PEG) Scale


Individuals rate

- 1. pain on average over the past week
- 2. how pain has interfered with **enjoyment of life**
- 3. how pain has interfered with **general activities**

0	1	2	3	4	5	6	7	8	9	10
No	bain									Pain as bad as you can imagine
	at nun vour <u>er</u>				s how,	during	g the p	ast we	ek, pa	iin has interfered
0	1	2	3	4	5	6	7	8	9	10
Doe	s not									Completely interferes
inte	fere									
. Wh					s how , 5	during 6	g the p 7	ast we	ek, pa 9	iin has interfered



Strong Link Between Pain & Mental Health



Based on data from Mental Health America online screening tool

 Proactively initiate conversations about mental health and chronic pain

 Include trauma, stress, anxiety, depression, PTSD, coping skills, and resilience-building; not just substance use-focused services and supports



SAMHSA's Definition of Trauma: The Three E's

An **event** of actual or extreme threat of physical or psychological harm which an individual **experiences** as traumatic, and which causes long-lasting **effects**.



Adverse Childhood Experiences (ACEs)

Potentially traumatic events that occur in childhood:

- Abuse: emotional, physical, and sexual
- Neglect: emotional and physical
- Household dysfunction: incarcerated relatives, mental illness, violence in household, marital issues/divorce, and substance use

Select Chronic Pain Conditions Associated with ACEs

 Dyspareunia, fibromyalgia, interstitial cystitis, migraines, and low back, orofacial, pelvic, or pregnancy-related pain



ATT N A Control Network -Juality Improvement Organizations INTERS FOR MEDICARE & MEDICAID SERVICES UALITY IMPROVEMENT & INNOVATION GROUP

Primary Care PTSD Screen (PC-PTSD-5)

Sometimes things happen to people that are unusually or especially frightening, horrible, or traumatic. Have you ever experienced this kind of event?

In the past month, have you...

- Had nightmares about the event(s) or thought about the event(s) when you did not want to?
- 2. Tried hard not to think about the event(s) or went out of your way to avoid situations that reminded you of the event(s)?
- 3. Been constantly on guard, watchful, or easily startled?
- 4. Felt numb or detached from people, activities, or your surroundings?
- 5. Felt guilty or unable to stop blaming yourself or others for the event(s) or any problems the event(s) may have caused?



QTTN QTCQ uality Innovation Network uality Improvement Organizations INTERS FOR MEDICARE & MEDICAID SERVICES WALITY IMPROVEMENT & INNOVATION GROUP

Patient Health Questionnaire for Depression

Over the last 2 weeks, how often have you been bothered by...

- 1. Little interest or pleasure in doing things
- 2. Feeling down, depressed, or hopeless
- 3. Trouble falling or staying asleep, or sleeping too much
- 4. Feeling tired or having little energy
- 5. Poor appetite or overeating
- 6. Feeling bad about yourself or that you are a failure or have let yourself or your family down

- 7. Trouble concentrating on things, such as reading the newspaper or watching television
- Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more
- 9. Thoughts that you would be better off dead or of hurting yourself in some way



Good Relationships Keep Us Happier & Healthier

Harvard Study of Adult Development, found 3 lessons :

- 1. Social connections are really good for us; loneliness kills
- 2. Quality of close relations matter
- 3. Good relationships protect bodies and brains



2015 Ted Talk: https://youtu.be/8KkKuTCFvzI



Screening for Social Isolation and Loneliness

UCLA Loneliness Scale

- 1. How often do you feel that you lack companionship?
- 2. How often do you feel left out?
- 3. How often do you feel isolated from others?

A Guide to Screening for Sc	ocial Isolation and Loneliness
Loneliness and social isolation can have significant health consequences, and most individuals are not aware of the risks. In the U.S., about 24% of individuals aged 65 and older are socially isolated. A considerable number of Americans aged 45 and older report feeling lonely. Individuals who identify as LGBTQIA+, racial / ethnic minorities, immigrants and older adupts are at increased risk of feeling lonely and being social isolated. These vulnerable populations tend to have fevere social connections due to language barriers, cultural differences, stigma, discrimination, and loss of family members and fineds. Loneliness is a subjective measure of an individual's perception of isolation that can be distressing because there is a discrepancy between their preferred and actual level of connectedness. Social isolation is an objective measure of deficits in social relationships, roles, and contact with others. Loneliness and social isolation are distinct conditions that should be identified independently to better understand the root cause of each, and determine the appropriate care pelan and support services.	Screen patients for loneliness Use the UCLA 3-Question Loneliness Scale to measure self-previewed connectedness: 1. "How often do you feel you lack companionship?" Hardly ever Some of the time Often 2. "How often do you feel left out?" Hardly ever Some of the time Often 3. "How often do you feel isolated from others?" Hardly ever Some of the time Often
There are significant health risks associated with loneliness and social isolation:	Patients screen positive for loneliness if they respond "some of the time" or "often" to any of the questions.
 Increased risk of mortality from all causes, similar to smoking, obesity, and physical inactivity. 	If a patient screens positive:
 Associated with a 29% and 32% increased risk of heart disease and stroke, respectively. Associated with higher rates of depression, anxiety, and suicide. Increase in doctor visits, hospitalization and readmissions among older adults. Increased risk of dementia by 50%. Vanto share their feelings due to stigma or discomfort and not know where to go for help or understand the erousness of the enoblem. Healthcare providers an play 	First, ask the patient if they would like help. If they say yes, refer them to support services. Please see the <u>Resources</u> action of this fiyer. Document and code* the results in the patient's electronic medical record: (<u>IO-10-CM Diagnosis Code 750-2</u> ((Problems related to living alone) • <u>ZG3.8</u> (Other specified problems related to primary support group) • <u>ZG3.9</u> (Problems related to primary support group)




patients-for-social-isolation-and-loneliness/

0IN-010

Qlarant

Substance Use Screening Tools



https://qi-library.ipro.org/2023/01/19/reimbursement-resources-for-screening-supporting-patients-with-substance-use-disorder/



Coding for Screening & Brief Intervention Services

Medicare Reimbursement		Cł	Medicaid Reimbursement neck with your state Medicaid agency about which billing codes to use.	Bundled Payments for Substance Use Disorders Under PFS		
HCPCS Code	Description	HCPCS Code	Description	HCPCS Code	Description	
G1028	Take-home supply of nasal Naloxone; 2-pack of 8mg per 0.1 mL nasal spray	G0396	Alcohol and/or substance (other than tobacco) abuse structured assessment	G2086	Office-based treatment for a substance use disorder, including development of the	
G2215	Take-home supply of nasal naloxone; 2-pack of 4mg per 0.1 mL nasal spray		(e.g., AUDIT, DAST-10), and brief intervention, 15 to 30 minutes		treatment plan, care coordination, individual therapy and group therapy and counseling; at	
G2011	Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST-10), and brief intervention, 5-14 minutes	G0397	Alcohol and/or substance (other than tobacco) abuse structured assessment (e.g., AUDIT, DAST-10), and intervention greater than 30 minutes	G2087	least 70 minutes in the first calendar month. Office-based treatment for a substance use disorder, including care coordination, individual therapy and group therapy	
tobacco) abuse structured ass (e.g., AUDIT, DAST-10), and br	Alcohol and/or substance (other than tobacco) abuse structured assessment	G0442	Annual alcohol misuse screening, 15 minutes		and counseling; at least 60 minutes in a subsequent calendar month.	
	(e.g., AUDIT, DAST-10), and brief intervention, 15 to 30 minutes	G0443	Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes	G2088	Office-based treatment for a substance use disorder, including care coordination,	
	Alcohol and/or substance (other than	G0444	Annual depression screening, 15 minutes		individual therapy and group therapy and counseling; each additional 30 minutes beyond the first 120 minutes. (List separately	
	tobacco) abuse structured assessment (e.g., AUDIT, DAST-10), and intervention	H0049	Alcohol/and/or drug screening			
greater than 30 minutes		H0050	Alcohol and/or drug services, brief intervention, per 15 minutes		in addition to code for primary procedure).	

IPRO QIN-QIO

Quality Innovation Network -Quality Innovation Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IQUALITY IMPROVEMENT & INNOVATION GROUP

Assessment Considerations

- Evaluate, select, and use valid, reliable tools appropriate to your practice and the needs of the individual
- Be aware of language, cognitive ability, age, culture, and disability factors
- Assess all aspects of pain: sensory, cognitive, cultural, behavioral, affective, etc.
- Recognize potentially higher risk populations: elderly, marginalized groups, people with past trauma, people with current or past history of substance use





Assessment Best Practices

- Recognize a patient's perception of pain, previous experiences with pain, current knowledge of pain, and spiritual/religious beliefs
- Schedule routine screening for all assessments
- Designate minimum frequency
- Document clearly and consistently to facilitate tracking
- Identify levels of pain that trigger assessment and intervention/planning
- Build referral pathways



Holistic Treatment Planning

Marghie Giuliano, R.Ph. Medication Safety Pharmacist Healthcentric Advisors




Realistic Goal Setting

- Reduce pain, improve comfort short & long term, and improve quality of life
- Maximize medications for effect and minimize side effects
- Improve strength and function
- Improve psychological status



Types of Pain




MMWR Recomm Rep 2022;71(No. RR-3):1–95. http://dx.doi.org/10.15585/mmwr.rr7103a1



Quality Innovation Network -Quality Innovement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IQUALITY IMPROVEMENT & INNOVATION GROUP


Multi-Modal Treatment Options





Quality Innovation Network -Quality Improvement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IQUALITY IMPROVEMENT & INNOVATION GROUP

Multi-Modal Treatment Options





How familiar are you with other treatment options in your community?





CDC Framework for Opioid Prescribing



- Benefits/risks
- Treatment goals & expectations
- Patient Contract

Selecting opioids and determining opioid dosages

- Opioid naive vs opioid tolerant
- PDMP
 - Incorporate into workflow/ designated authority
- Lowest effective dosage of immediate release/ shortest duration of therapy

Deciding duration of initial prescription and conducting follow-up

> Monitor between 1 – 4 weeks with an exit plan in mind

- Acute vs
 Chronic
- PDMP to monitor

Healthcer
 Advisors
 Qlarant

QIN-QIO

 Baseline assessment



MMWR Recomm Rep 2022;71(No. RR-3):1–95. DOI: http://dx.doi.org/10.15585/mmwr.rr7103a1

Other Important Considerations


Assessing Risk/Addressing Potential Harm of Opioid Use

- Prescription drug monitoring programs
 - Incorporate into workflow designate authority
 - Set and check PDPM alerts
- Naloxone with every opioid prescription
- · Co-prescribing, drugs to avoid
- Side effects to manage constipation
- Tapering plan
 - Avoid rapid tapers or sudden opioid discontinuation
 - Monitor withdrawal symptoms





Tools to Support Awareness & Education



- Patient Agreement/Contracts
- **o** Medication Education
 - Use <u>Teach Back</u> method
 - Encourage patients to know the <u>ABCDs</u>
- $_{\circ}\,$ Med disposal locations
- Drug Take Back days



Quality Innovation Network -Quality Improvement Organizations CENTERS FOR MEDICARE & MEDICAID SERVICES IQUALITY IMPROVEMENT & INNOVATION GROUP

Assess physiological and behavioral needs and risks

Identify patient-centered **treatment** plan that reduces both suffering and unintended harm

Implement and **refer**, as needed, including complementary therapies Follow up to provide support and **monitor progress**





Panel Discussion





Rebekah Gardner, MD Senior Medical Scientist Healthcentric Advisors



Marghie Giuliano, R.Ph. Medication Safety Pharmacist Healthcentric Advisors



Jennifer McCarthy, EdD, LCPC Grants and Contracts Manager New England Rural Health Association



Connect.	Educational		
Contribute.	Series		
Improve.	Healthcentric Advisors Qlarant Qlarant Qlarant Qlarant		

Reserve Your Seat for the Remaining Sessions

Date & Time	Торіс
5/25 11am-12pm	Opioid Use Disorder: Paving the Way for Evidence Base Care across the Continuum
6/22 11am-12pm	Supporting the Recovery Journey with Community Connections
7/27 11am-12pm	Bringing it All Together

View all educational opportunities on <u>IPRO QIN-QIO event page</u>

